Annotation Detail

Information
Associated Genes
FGFR2
Associated Variants
FGFR2 FGFR2-TACC3
Associated Disease
cholangiocarcinoma
Source Database
CIViC Evidence
Description
In a 43 year old female patient with this fusion in intrahepatic cholangiocarcinoma. Both pazopanib and ponatinib separately resulted in minor tumor shrinkage. This fusion is also shown to be recurrent in multiple other cancer types.
Variant Origin
somatic
Variant Origin
Somatic
Evidence URL
https://civic.genome.wustl.edu/links/evidence_items/296
Gene URL
https://civic.genome.wustl.edu/links/genes/22
Variant URL
https://civic.genome.wustl.edu/links/variants/54
Rating
3
Evidence Type
Predictive
Disease
Cholangiocarcinoma
Evidence Direction
Supports
Drug
Ponatinib,Pazopanib
Evidence Level
C
Clinical Significance
Sensitivity/Response
Pubmed
24550739
Drugs
Drug NameSensitivitySupported
PazopanibSensitivitytrue
PonatinibSensitivitytrue